Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH.
Department of Medicine, Division of Hematology-Oncology, University of North Carolina, Chapel Hill, NC, USA.
K
K
Martin
Thrombosis Research Unit, Center for Vascular Diseases, University Hospital, Technische Universität Dresden, Dresden, Germany.
J
J
Beyer-Westendorf
Division of Pulmonary and Critical Care Medicine, University of Washington School of Medicine, Seattle, WA, USA.
B L
BL
Davidson
Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands.
M V
MV
Huisman
Department of Hematology, Oslo University Hospital and University of Oslo, Oslo, Norway.
P M
0000-0001-5556-8099
PM
Sandset
Department of Medicine, Division of Hematology-Oncology, University of North Carolina, Chapel Hill, NC, USA.
S
S
Moll
D000284:Administration, Oral; D000991:Antithrombins / Q000008:administration & dosage* / Q000009:adverse effects; D001281:Atrial Fibrillation / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D001777:Blood Coagulation / Q000187:drug effects*; D065427:Factor Xa Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D006405:Hematology / Q000592:standards*; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D009765:Obesity / Q000097:blood / Q000150:complications* / Q000175:diagnosis; D018570:Risk Assessment; D012307:Risk Factors; D020521:Stroke / Q000097:blood / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome; D054556:Venous Thromboembolism / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*
D000991:Antithrombins; D065427:Factor Xa Inhibitors